Home Blog Page 1431

Heartbeats Shareholder Mr Lu Min Yong Honoured as “Global Chinese Role Model” at the 2026 Spring Festival Gala Evening

By
Advertorial Desk
-

SYDNEY and BEIJING, Jan. 27, 2026 /PRNewswire/ — Heartbeats proudly congratulates its shareholder, Lu Min Yong, on being awarded the title of “全球华人楷模” (Global Chinese Role Model) at the Global Chinese Spring Festival Gala Evening held as part of the 2026 Chinese New Year celebrations in Beijing, China.

This honour recognises Mr Yong’s exceptional contribution to business leadership, cross-border collaboration, and nation-building infrastructure, most notably through his leadership of CREGA Australia Pty Ltd, which played a critical role in Australia’s landmark Sydney Western Harbour Tunnel.

Through CREGA’s partnership with global engineering leaders, Mr Yong helped deliver some of the most advanced large-diameter tunnel boring machines ever deployed in the Southern Hemisphere. These achievements not only set new technical benchmarks for Australian infrastructure, but also demonstrated how precision engineering, long-term vision, and international cooperation can deliver projects of national significance. The Harbour Tunnel project stands as a defining example of Mr Yong’s ability to translate ambition into execution at the highest level.

Beyond infrastructure, Mr Yong’s story is also one of personal discipline and deep respect for science. Now in his 70s, he continues to lead and oversee multiple large-scale businesses across property, engineering, hospitality, sport, green technology, and health. He has never viewed age as a signal to slow down, because, in his words, success is sustained not by time, but by vitality.

This belief is what naturally connects Mr Yong to Heartbeats AU Pty Ltd. As a strong advocate of evidence-based thinking, he sees health not as a lifestyle trend, but as strategic infrastructure for human performance. The philosophy behind Heartbeats, adding life into years, not just years into life resonates deeply with his own experience. It is this foundation of physical resilience, mental clarity, and purpose that enables him to remain fully engaged, decisive, and forward-looking well beyond the age when many consider retirement.

Heartbeats was founded by Professor Hosen Kiat, one of the world’s most highly cited clinical cardiologists, to translate rigorous medical science into practical, everyday guidance for long-term health and longevity. Mr Yong’s support reflects a shared conviction: that the next era of leadership whether in infrastructure, business, or society will be defined by those who understand health as the ultimate enabler of sustained impact.

“True longevity is not about stepping back,” Mr Yong said. “It is about having the capacity, physically and mentally to continue building, contributing, and leading. Heartbeats represents that philosophy grounded in science.”

As Heartbeats continues to expand its global education and preventive health initiatives, Mr Lu Min Yong’s journey from delivering nation-shaping infrastructure to championing human longevity stands as a powerful example of how science, purpose, and endurance can shape a life without limits.

Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma

By
Advertorial Desk
-

SAN FRANCISCO and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announced that its anti-GPRC5D/BCMA/CD3 tri-specific antibody IBI3003 has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of relapsed or refractory multiple myeloma, (R/R MM) in patients who have received four or more lines of previous anti-myeloma therapies, that include at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody.

IBI3003 was discovered and developed using Innovent’s proprietary Sanbody® platform and its development is being advanced globally. IBI3003 is currently undergoing a Phase 1/2 clinical trial in patients with relapsed or refractory multiple myeloma in China and Australia, and there are plans to initiate a Phase 1/2 clinical trial in the United States imminently.

Clinical data presented at the American Society of Hematology (ASH) Annual Meeting on December 7, 2025[Link], demonstrated a tolerable safety profile and promising efficacy signals for IBI3003 in patients who had failed ≥2 prior lines of myeloma therapy:

  • Thirty-nine patients with R/R MM who had previously received at least a PI, an IMiD, and an anti-CD38 monoclonal antibody were treated with IBI3003 at dose levels ranging from 0.1 μg/kg to 800 μg/kg and underwent at least one tumor assessment after baseline. As of the data cutoff date of November 7, 2025, the median follow-up duration was 3.25 months (range: 0.4–7.4), and the median treatment duration was 12.14 weeks (range: 1.0–33.0).
  • Among patients treated at doses ≥120 μg/kg (n=24), the overall response rate (ORR) was 83.3%, including 4 stringent complete responses (sCR), 7 very good partial responses (VGPR), and 9 partial responses (PR). In this cohort, the ORR was 80% among 10 patients with extramedullary disease (EMD) and 77.8% among 9 patients previously treated with BCMA- and/or GPRC5D-directed therapies. Among patients who achieved complete response or better, the minimal residual disease (MRD) negativity rate was 100% (n=4), as assessed by validated next generation sequencing, with a threshold of 10-5, performed at a central laboratory.
  • All cases of cytokine release syndrome (CRS) were Grade 1-2, with only 2 cases of Grade 1-2 immune effector cell-associated neurotoxicity syndrome (ICANS) reported. Most treatment-emergent adverse events (TEAEs) related to GPRC5D targeting, including those affecting the oral cavity, skin, and nails, were Grade 1–2, with two patients experiencing Grade 3 rash.

Dr. Hui Zhou, Chief R&D Officer of Oncology in Innovent, stated, “IBI3003 monotherapy has demonstrated encouraging efficacy and a favorable safety profile in R/R MM patients who had received three or more prior lines of therapy. Notably, meaningful clinical activity was observed even in high-risk patients with EMD or those previously treated with anti-BCMA and/or GPRC5D-targeted therapies, highlighting IBI3003’s potential to address key unmet needs. Its overall manageable safety profile further supports continued investigation and the potential for durable survival benefit. The Fast Track Designation granted by the U.S. FDA represents an important milestone in the global development of IBI3003, and we look forward to further evaluating its potential to benefit patients worldwide.”

Fast Track Designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and address unmet medical needs. Programs granted FTD benefit from more frequent interactions with the FDA, which may accelerate clinical development and regulatory review.

About IBI3003 (Anti-GPRC5D/BCMA/CD3 Trispecific Antibody)

IBI3003 is a tri-specific TCE developed using Innovent’s proprietary Sanbody® platform to target both GPRC5D and BCMA. The molecule is designed to mitigate tumor escape associated with single-antigen targeting. In preclinical studies, IBI3003 demonstrated superior in vitro and in vivo antitumor activity compared with marketed benchmark T-cell engagers, including in cell lines and xenograft models with low BCMA and GPRC5D expression. A Phase 1/2 clinical trial (NCT06083207) is ongoing in China and Australia. In December 2025, IBI3003 received IND approval from the U.S. FDA, enabling initiation of a Phase 1/2 clinical trial in the United States.

About Multiple Myeloma

Multiple myeloma (MM) is a malignant hematologic disease characterized by the clonal proliferation of plasma cells and is the second most common hematologic malignancy [1]. MM remains incurable, and factors such as inadequate depth of response, extramedullary involvement, and short remission duration are associated with poor prognoses [2]. For patients with R/R MM who have received four or more prior lines of therapy, including exposure to PIs, IMiDs, and anti-CD38 antibodies, treatment options include, but are not limited to, BCMA-targeted CAR-T therapies and bispecific antibodies targeting CD3×BCMA or CD3×GPRC5D. However, the benefits of these approaches may be limited by antigen loss and treatment resistance [3].

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References:

[1] Wang S, Xu L, Feng J, et al. Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis. Front. Oncol. 2019;9:1513.

[2] Chinese Hematology Association, Chinese Society of Hematology. [Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)]. Zhonghua Nei Ke Za Zhi. 2022;61(5):480-487.

[3] Li C, Wang D, Song Y, et al. CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1). J. Clin. Oncol. 2023;41(16_suppl):8025-8025.

 

Reeracoen Study Finds Malaysian Employers Taking a More Targeted Approach to Hiring in 2026

By
Advertorial Desk
-

Tighter labor market and rising costs prompt shift toward skills-aligned recruitment

KUALA LUMPUR and PENANG, Malaysia, Jan. 27, 2026 /PRNewswire/ — Reeracoen Malaysia has released its Hiring Trends Year-on-Year Comparison 2024 vs. 2025, showing that while Malaysian employers continued to hire in 2025, recruitment strategies are becoming more selective, disciplined, and aligned with long-term workforce needs. Employers are shifting away from broad recruitment drives toward more selective, skills-aligned hiring that supports long-term workforce sustainability.

The change comes as organisations navigate higher employment costs, ongoing skills mismatches, and tighter labour market conditions. Rather than scaling back hiring, the findings suggest a recalibration—a move toward hiring the right talent at the right time, not simply expanding headcount.

Report overview: Comparing Hiring Patterns Across Two Years

The annual study analyses hiring data across Malaysian industries, comparing actual recruitment outcomes in 2024 with employers’ hiring intentions and behaviours in 2025.

While demand for talent remains strong, employers are moving away from large hiring waves. Instead, they are implementing phased, targeted recruitment plans that prioritise roles essential to productivity and business growth. This shift reflects a broader recognition that talent acquisition is a strategic function, not just an operational task.

Why Employers Are Rethinking Hiring Approaches

The report identifies several key factors driving this shift. Rising labour costs, including wage adjustments under Budget 2025, combined with ongoing skills mismatches, have made each hiring decision more significant. Meanwhile, talent shortages in specialized and technical roles increase the risks and costs associated with hiring errors.

Despite these pressures, overall hiring demand remains stable, with employers focusing resources on roles that directly support productivity and growth.

In response, employers are re-evaluating how, when, and whom they hire. Job readiness, relevant experience, and long-term fit are now taking precedence over volume. Market benchmarking and robust candidate assessments are becoming standard tools in the hiring process.

Yohei Yagi, Country Manager at Reeracoen Malaysia, noted that this evolution is evident across multiple sectors.

“Malaysian employers are still hiring, but they’re doing so with greater precision than in previous years,” Yagi said. “Higher employment costs and ongoing skills gaps mean organisations need to be more deliberate in their hiring decisions. What we are seeing is a shift toward well-defined, skills-aligned hiring rather than broad expansion.”

Why the Report Matters for Employers

The study positions recruitment as a strategic lever that directly influences organisational resilience and competitiveness. The stakes are higher than ever: a single mis-hire can affect productivity, team dynamics, and long-term cost efficiency.

Kenji Naito, Group Chief Executive Officer of Reeracoen Group, said this growing awareness is shaping recruitment across the region.

“Across Asia-Pacific, employers are navigating tighter labour markets and rising workforce costs at the same time,” Naito said. “In Malaysia, this has led to a more disciplined approach to hiring, where accuracy and long-term fit matter more than speed or volume. Recruitment partners play an important role in helping organisations interpret market conditions and make informed, sustainable hiring decisions.”

Reeracoen developed the Hiring Trends Comparison as an annual study to help business leaders and HR professionals respond to shifting market conditions with clarity and confidence. The report provides actionable insights and benchmarks to guide more strategic workforce planning.

For employers, success in 2026 will increasingly depend on the ability to hire the right skills at the right time, supported by accurate market data and informed recruitment strategies.                        

To access the full report and explore Reeracoen Malaysia’s hiring insights and recruitment solutions, please visit: https://www.reeracoen.com.my.

About Reeracoen Malaysia

Reeracoen Malaysia is part of Reeracoen Group, an award-winning leader in Asia’s recruitment landscape, connecting top-tier talent with forward-thinking organisations. With nine offices across six major Asian countries, Reeracoen combines deep local expertise with cross-border hiring capabilities to help businesses grow stronger and faster. We uphold the highest standards of professionalism and service quality, delivering innovative and trusted recruitment solutions that meet the evolving needs of today’s workforce.

WireBarley Partners with LAFC in First Deal for Korean Fintech

By
Advertorial Desk
-

SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ — Global fintech company WireBarley has announced a multi-year strategic partnership with Los Angeles Football Club (LAFC), becoming the club’s Official Remittance Partner and the first Korean fintech company to partner with a Major League Soccer team.

Larry Freedman, Co-President of Los Angeles Football Club (LAFC), and Yoonha Lina Jeon, CMO and North America Managing Director of WireBarley.
Larry Freedman, Co-President of Los Angeles Football Club (LAFC), and Yoonha Lina Jeon, CMO and North America Managing Director of WireBarley.

The collaboration unites two brands built on global connectivity, trust, and community. As one of Major League Soccer’s most internationally recognized clubs, LAFC embodies the diverse, global culture of Los Angeles—an identity that closely aligns with WireBarley’s mission to make cross-border money transfers more accessible, transparent, and reliable for people around the world.

WireBarley specializes in connecting customers across Asia-Pacific markets—including Korea, Australia, New Zealand, Hong Kong SAR, and Vietnam—with North America. Now through its LAFC partnership, the company aims to build stronger connections with Asian American communities in the U.S. while gaining visibility among the team’s globally connected fans.

As part of the partnership, WireBarley will receive marketing rights within Los Angeles and designated international territories, along with digital and social integrations designed to engage fans through compelling content, sweepstakes, and matchday experiences. The collaboration will emphasize shared values of innovation, inclusivity, and global perspective—core pillars for both organizations.

“We are extremely excited to partner with WireBarley given their focus on connecting people from various countries and spanning different cultures,” said LAFC Co-President Larry Freedman. “Playing in Los Angeles, a city that serves as one of the most globally connected cities in the world, this was a natural fit as we seek to reflect the identity of our fanbase.”

The partnership further strengthens LAFC’s growing portfolio of international and technology-driven partners, reinforcing the club’s position at the intersection of sport, culture, and global community. 

“We are honored to partner with LAFC, a club renowned for its excellence and dedication to fans,” John Joongwon Yoo, CEO and Co-founder of WireBarley. “This partnership extends beyond the pitch to connect communities and create meaningful experiences. It will bring fans in Los Angeles and our global customers in countries including Korea, Australia, and beyond closer to LAFC through engaging matchday and interactive online experiences that celebrate the club’s spirit and passion.”

WireBarley provides international remittance services across 46 countries, with operations in seven key markets: Korea, the U.S., Canada, Australia, New Zealand, Vietnam, and Hong Kong SAR (temporarily suspended). The company has recorded over 2.2 million app downloads and 1.1 million registered users worldwide, establishing itself as a leading digital remittance platform in the Asia-Pacific region.

How to Choose the Right Oxygen Concentrator in 2026: A Look at VARON’s Latest Lineup

By
Advertorial Desk
-

NEW YORK, Jan. 27, 2026 /PRNewswire/ — As oxygen support technology continues to advance, choosing the right oxygen concentrator in 2026 is no longer about selecting a single “best” model—it’s about identifying the right solution for daily routines, mobility needs, and oxygen delivery requirements.

With users increasingly balancing home use, outdoor activity, and travel, VARON’s latest lineup reflects a structured approach, helping users clearly distinguish between portable performance, consistent home supply, and supportive daily-use solutions.

Key Buying Factors for Oxygen Concentrators in 2026

Before choosing a model, users should consider three main factors:

1. Home Use vs. On-the-Go
Home oxygen concentrators provide stable, continuous oxygen with quiet operation for long daily use. Portable oxygen concentrators focus on mobility, battery life, and lightweight design, supporting activity outside the home.

2. Continuous Flow vs. Pulse Flow
Continuous flow delivers oxygen steadily, ideal for consistent daily needs. Pulse flow delivers oxygen in bursts during inhalation, allowing smaller, lighter designs with longer battery life—perfect for short outings or travel.

3. Output Range and Flexibility
Adjustable flow settings provide flexibility, but users should check how consistently oxygen concentration is maintained across settings on different models, especially for extended use.

Start with Mobility: Portable Oxygen Concentrators in 2026

For many users, portability has become a primary consideration. Modern portable oxygen concentrators must strike a careful balance between oxygen delivery strength, battery performance, and ease of movement.

VP-8G vs. VP-8 Lite — Performance & Portability 

VP-8G and VP-8 Lite portable oxygen concentrators are built on the same advanced platform, sharing size, weight, and core features. The key difference is performance versus endurance.

As VARON’s flagship portable model, VP-8G portable oxygen concentrator delivers higher oxygen output with up to 8 pulse settings and clinical-grade 93% ±3% oxygen, all within a compact, lightweight body of 4.37 lbs—ideal for users with higher oxygen demands or more intensive daily activity.

By contrast, the VP-8 Lite small portable oxygen concentrator trades peak performance for longer battery life and affordability, making it well suited for users with moderate oxygen needs who value everyday mobility and extended usage.

VP-6 — Continuous Flow Portability for All-Day Use

The VP-6 oxygen concentrator is a continuous portable oxygen concentrator designed for users who require steady oxygen delivery beyond the home. Bridging the gap between stationary systems and portable pulse devices, it is ideal for all-day use, especially for users who prefer continuous flow.

VP-1 & VP-2 — Practical Pulse Flow Options for Everyday Mobility

The VP-1 and VP-2 portable oxygen concentrators represent standard, well-rounded portable options, providing reliable pulse flow support for users with moderate oxygen needs. The VP-2 portable oxygen concentrator offers smart pulse delivery and a long-lasting, replaceable battery. While the VP-1 portable oxygen concentrator is a budget-friendly entry-level option, ideal for shorter outings or occasional use. Together, they deliver easy-to-use, dependable solutions for everyday portable oxygen needs.

The Portable Series allows users to select a model based on activity level, oxygen demand, and portability expectations, rather than a one-size-fits-all approach.

Home & Stationary Oxygen Solutions

For users whose oxygen needs are primarily home-based—especially those requiring higher stability and extended daily operation—VARON offers a dedicated group of stationary oxygen solutions.

Serene 5 & Serene 3 — Clinical-Grade Oxygen Supply for Home Use

The Serene Series delivers clinical-grade, continuous oxygen for users who rely on a stable and consistent supply throughout the day. Features such as caster wheels, humidification support, and low-noise operation make these models well suited for comfortable, care-free daily use.

Serene 5 stationary oxygen concentrator supports higher-capacity needs, delivering up to 5 LPM of 93% ±3% oxygen

Serene 3 stationary oxygen concentrator offers a lower-flow alternative while maintaining clinical-grade concentration at 1–3 LPM

VH Series — Supportive Oxygen for Moderate Daily Use

The VH Series (VH-1 through VH-4) supports users with milder daily oxygen needs, focusing on ease of use rather than maximum output:

VH-1 to VH-3 home oxygen concentrator provide straightforward continuous flow support for daily routines. VH-4 home oxygen concentrator , the latest model in the series, introduces wheel-assisted mobility, improving convenience for indoor movement

Positioned alongside the standard VH series models, the VH-2 Pro Wheel Edition home oxygen concentrator features enhanced performance with in-home mobility, making it a go-to choice for users with mild to moderate oxygen needs who want added convenience.

Ultra Lightweight & Travel-Focused Options

Designed for users with mild oxygen needs, VARON’s Light Series (VL-1 and VL-2) are lightweight portable oxygen concentrator that offers compact, easy-to-carry solutions with simple operation, perfect for short outings. For users who frequently travel by car, the VT-1 Travel Oxygen Concentrator offers dual-mode operation (continuous & pulse) and multiple power options, ensuring uninterrupted oxygen supply at home, in the vehicle, or on the go.

Oxygen Concentrator Accessories for Long-Term Support

VARON’s lineup is supported by a full range of accessories and replacement parts, including nasal cannulas, filters, batteries, and carrying bags. This ecosystem ensures long-term usability and easier maintenance across both home and portable oxygen concentrators.

VARON’s Commitment in 2026

In 2026, VARON continues to focus on clarity, reliability, and long-term user support. By offering a clearly structured lineup—from high-performance portable devices to clinical-grade home systems—the company helps users make confident, informed choices that support everyday life.

Media Contact:

VARON Oxygen Concentrator

Email: official@varoninc.com

Website: www.varoninc.com

Tineco Brings Smarter Floor Care Solutions to Modern Homes This Winter

By
Advertorial Desk
-

SEATTLE, Jan. 27, 2026 /PRNewswire/ — As modern homes continue to evolve, consumers are increasingly looking for appliances that strike the right balance between performance, design, and practicality. Tineco, a global leader in intelligent floor care solutions, brings this philosophy to life through a refined product portfolio designed to support modern living with smarter, more balanced cleaning experiences.

By combining advanced technology with user-centric design, Tineco’s latest range addresses a broad spectrum of household needs — from effective wet-dry floor care to effortless cordless vacuuming — all while remaining intuitive and accessible for everyday use.


Designed for effortless cleaning in hard-to-reach spaces

For homes where dust and debris tend to accumulate under furniture and along edges, FLOOR ONE Stretch S6 makes thorough floor cleaning simpler and more efficient. Its 180° lay-flat design slides seamlessly beneath beds, sofas, and low cabinetry, helping remove dust and allergens from areas that are often overlooked during routine cleaning.

Triple-sided edge cleaning reaches as close as 0.2 inches from skirting boards, while up to 40 minutes of runtime supports uninterrupted cleaning across rooms. Powered by iLoop™ Technology, the Stretch S6 automatically adjusts performance based on the mess detected, allowing users to focus on their space rather than the settings. After cleaning, the FlashDry™ Self-Cleaning System rinses and dries the entire unit, keeping it fresh and ready for the next use.

→ Available via Amazon from January 27 to February 1, with a promotional price of AUD $429 and savings of 52%.

Designed for flexible, whole-home cleaning without compromise

For households seeking one tool that adapts easily to different cleaning tasks, FLOOR ONE Switch S7 Stretch delivers true multi-function versatility. Designed as a 5-in-1 solution, it transitions effortlessly between floor washing and vacuuming, handling wet and dry messes, hard floors, furniture surfaces, and hard-to-reach crevices throughout the house.

At the core of this flexibility is SwitchPro Motor, which enables smooth switching between modes without interrupting cleaning. DualBlock Anti-Tangle and ZeroTangle brush designs work together to prevent hair and pet fur from wrapping around the brush, ensuring consistent performance with minimal maintenance. After use, the upgraded FlashDry™ Self-Cleaning System uses 85°C heated water and hot air to thoroughly clean and dry internal components, delivering a more hygienic and hassle-free ownership experience.

→ Available via Amazon from January 27 to February 1, with a promotional price of AUD $849 and savings of 29%.

Designed for everyday performance with an artistic touch

For households that value both performance and design, FLOOR ONE S9 Artist brings together full-featured floor care and an elegant, artist-inspired aesthetic. Built for high-efficiency everyday use, it delivers smooth steering, effortless manoeuvrability, and edge-to-edge reach, allowing users to move easily from room to room.

SmoothDrive™ Technology supports responsive handling, while a low-profile, 180° lay-flat design provides access beneath furniture. A dynamic display with shifting 3D lighting, combined with an LED headlight, offers clear, real-time guidance throughout the cleaning process. With up to 75 minutes of runtime, the S9 Artist is designed for uninterrupted cleaning sessions that feel intuitive and refined.

→ Available via Amazon from January 27 to February 1, with a promotional price of AUD $899 and savings of 25%.

For smaller homes or shorter cleaning routines, FLOOR ONE S7 Artist offers a streamlined alternative, delivering up to 50 minutes of runtime and the same design-led experience, just without the SmoothDrive™ system.

→ Available via Amazon from January 27 to February 1, with a promotional price of AUD $679 and savings of 24%.

Designed for low-maintenance, worry-free vacuuming

For busy households that want to minimise hands-on maintenance, PURE ONE Station 5 transforms cordless vacuuming into a cleaner, more automated routine. Its 3-in-1 Smart Station charges, stores, and automatically empties the dustbin, holding up to 45 days of debris without manual contact.

With 175W of suction power, a 120° wide green LED headlight, and a ZeroTangle brush head, the Station 5 captures everything from fine dust to pet hair across floors and elevated surfaces. Up to 70 minutes of runtime supports whole-home cleaning, while a 2-in-1 crevice brush with an extendable tube makes it easier to reach shelves, curtains, ceiling corners, and other high or narrow spaces. The result is a practical, efficient solution that fits seamlessly into everyday living.

→ Available via Amazon from January 27 to February 1, with a promotional price of AUD $559 and savings of 30%.

About Tineco

Tineco (“tin-co”) was founded in 1998 with its first product launch as a vacuum cleaner and, in 2019, pioneered the first-ever smart vacuum. Today, the brand has evolved into a global leader in intelligent appliances spanning floor care, kitchen, and personal care categories. With a growing user base of over 23 million households and availability in approximately 30 countries worldwide, Tineco remains committed to its brand vision of making life easier through smart technology and continuous innovation. For more information, visit au.tineco.com.

TIAN RUIXIANG Holdings Ltd. Announces Receipt of Nasdaq Delisting Notification Regarding Minimum Bid Price Deficiency

By
Advertorial Desk
-

BEIJING, Jan. 27, 2026 /PRNewswire/ — TIAN RUIXIANG Holdings Ltd. (Nasdaq: TIRX) (the “Company” or “TRX”) today announced that it had received a written notification (the “Notice”) from the Listing Qualifications (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on January 20, 2026, indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). This determination was based on the fact that the bid price of the Company’s listed securities had closed at less than $1 per share over the prior 30 consecutive business days.

Pursuant to the Notice, normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Listing Rule 5810(c)(3)(A) due to the fact that the Company has effected a reverse stock split over the prior one-year period. As a result, the Staff determined to delist the Company’s securities from The Nasdaq Capital Market.

The Company requested a hearing before the Nasdaq Hearings Panel (the “Panel”) on January 22, 2026, to appeal the Notice and to address compliance with the Minimum Bid Price Requirement. This hearing request has stayed the delisting of the Company’s securities pending the Panel’s decision. Consequently, the Company’s securities will continue to trade on The Nasdaq Capital Market while the appeal process is pending.

On January 22, 2026, Nasdaq notified the Company that the hearing is scheduled to be held on February 17, 2025. The Company intends to present a plan to regain compliance to the Panel. However, there are no assurances that the Company will be able to regain or maintain compliance with the Minimum Bid Price Requirement or any other Nasdaq listing standards, that Nasdaq will grant the Company any extension of time to regain compliance with the Minimum Bid Price Requirement, or that any such appeal to the Panel will be successful, as applicable.

About TIAN RUIXIANG Holdings Ltd

TIAN RUIXIANG Holdings Ltd, headquartered in Beijing, China, is an insurance broker operating in China through its China-based variable interest entity. It distributes a wide range of insurance products, which are categorized into two major groups: (1) property and casualty insurance, such as commercial property insurance, liability insurance, accidental insurance, and automobile insurance; and (2) other types of insurance, such as health insurance, life insurance, and other miscellaneous insurance.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These include statements regarding future plans, objectives, expectations and intentions, and involve known and unknown risks and uncertainties. Words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “continue,” or similar expressions identify these statements. These forward-looking statements are based on current expectations and assumptions and are not guarantees of future performance; actual results may differ materially. TIAN RUIXIANG Holdings Ltd. undertakes no obligation to update these statements for subsequent events or circumstances, except as required by law.

For investor and media enquiries, please contact: 
TIAN RUIXIANG Holdings Ltd 
Investor Relations Department
Email: ir@tianrx.com 

Johnson Controls Appoints Susan Hughes to lead Asia Pacific Region

By
Advertorial Desk
-

Seasoned leader to strengthen execution and accelerate growth opportunities in the Asia Pacific region

CORK, Ireland, Jan. 27, 2026 /PRNewswire/ — Johnson Controls (NYSE: JCI), a global leader for smart, healthy and sustainable buildings, today announced the appointment of Susan Hughes as vice president and president, Asia Pacific. Hughes will report to CEO Joakim Weidemanis and join the company’s executive committee. She succeeds Anu Rathninde, who will depart Johnson Controls at the end of February.

“As we continue to operationalize our enterprise strategy, the Asia Pacific region represents a significant growth opportunity,” said Joakim Weidemanis, CEO, Johnson Controls. “With her deep expertise in the region and strong record of leading teams, operations and customer engagement, across the region, Susan is well positioned to strengthen our execution, deliver even greater value for our customers, enable our people to do so and ultimately accelerate growth.

“I want to thank Anu for his dedication and contributions to Johnson Controls over the last few years and wish him well.”

Hughes brings decades of operating experience across sales, marketing, service, engineering, and manufacturing. During her 20-year career at Emerson, she held leadership roles across multiple businesses in the Asia Pacific region. She recently served as President of Asia Pacific for Emerson Automation Solutions, where she delivered sustained growth across diverse markets in the region, through commercial execution and lifecycle services.  

Hughes holds an MBA from Washington University’s Olin School of Business and dual bachelor’s degrees in Mathematics and Mandarin Chinese from Grinnell College. She is conversant in both English and Mandarin Chinese. 

About Johnson Controls 

At Johnson Controls (NYSE:JCI), we transform the environments where people live, work, learn and play. As the global leader in smart, healthy and sustainable buildings, our mission is to reimagine the performance of buildings to serve people, places and the planet.  

Building on a proud history of 140 years of innovation, we deliver the blueprint of the future for industries such as healthcare, schools, data centers, airports, stadiums, manufacturing and beyond through OpenBlue, our comprehensive digital offering.  

Today, Johnson Controls offers the world`s largest portfolio of building technology and software as well as service solutions from some of the most trusted names in the industry.  

Visit johnsoncontrols.com for more information and follow @Johnsoncontrols on social platforms. 

INVESTOR CONTACT:

MEDIA CONTACT:

Mike Gates

Danielle Canzanella

Direct: 414.524.5785

Direct: 414.524.8687

Email: Michael.j.gates@jci.com

Email: Danielle.canzanella@jci.com

 

Susan Hughes has been appointed vice president and president, Asia Pacific for Johnson Controls.
Susan Hughes has been appointed vice president and president, Asia Pacific for Johnson Controls.

 

 

1...1,4301,4311,432...6,709Page 1,431 of 6,709